Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3872 participants.
Also called NCT02876835
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 3,872 participants
- Sponsor
- Registry
-
NCT02876835 -
2016-000542-65
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Colombia, Czechia, Denmark, Estonia, France, Germany, Greece, Hong Kong SAR China, Hungary, India, Israel, Italy, Malaysia, Mexico, Netherlands, New Zealand, Philippines, Poland, Portugal, Romania, Russia, Singapore, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Türkiye, Ukraine, United Kingdom, Vietnam
- Registry status
- Completed
Technical summary
Registry record NCT02876835. Randomized; no masking; primary purpose treatment. Start 2016-09-27 (actual); primary completion 2021-04-19 (actual). Results posted on 2022-04-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
- Condition
- Anaemia
- Intervention (Drug)
- Daprodustat
- Intervention (Drug)
- Darbepoetin alfa
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Iron Therapy
- Lead sponsor
- GlaxoSmithKline
Record details
- Record id
cardio:ct-nct02876835- Content hash
9b00828b6dd9570b69ba5b42fee6d3f86892f618666bdc6ddcbaacda73dc87f7